Therapy of chonic non infectious uveitis;Traitement des uvéites chroniques non infectieuses

Revue de Medecine Interne

Volumn 28, Issue 4, 2007, Pages 232-241

  Le Thi Huong, D ^a   Cassoux, N ^a   Lebrun Vignes, B ^a   Wechsler, B ^a   Bodaghi, B ^a   Lehoang, P ^a   Piette, J C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Biotherapy; Immunosuppressor; Therapy; Uveitis

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ALPHA2A INTERFERON; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; ETANERCEPT; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERFERON; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; PREDNISONE; PREDNISONE ACETATE; TACROLIMUS; TUMOR NECROSIS FACTOR; BIOLOGICAL RESPONSE MODIFIER;

ABDOMINAL PAIN; ANKYLOSING SPONDYLITIS; BEHCET DISEASE; BIOLOGICAL THERAPY; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERKALEMIA; HYPERTENSION; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; LUNG DISEASE; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; PANCREAS DISEASE; POLYARTERITIS NODOSA; PSORIATIC ARTHRITIS; RHEUMATIC FEVER; SHORT SURVEY; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSPLANTATION; TREMOR; UVEITIS; VOMITING; WEGENER GRANULOMATOSIS; REVIEW;

ADRENAL CORTEX HORMONES; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; UVEITIS;

EID: 33947585965     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2006.10.326     Document Type: Short Survey

References (56)

1. Bodaghi B., Cassoux N., Wechsler B., Hannouche D., Fardeau C., Papo T., et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore) 80 (2001) 263-270
2. The SUN working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international worshop. Am. J. Ophthalmol. 140 (2005) 509-516
3. Jabs D.A., Rosenbaum J.T., Foster C.S., Holland G.N., Jaffe G.J., Louie J.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders : recommendations of an expert panel. Ophthalmology 130 (2000) 492-513
4. Okada A.A. Non infectious uveitis. A scarcity of randomized clinical trials. Arch. Ophthalmol. 123 (2005) 682-683
5. Travis L.B., Curtis R.E., Stovall M., Holowaty E.J., van Leeuwen F.E., Glimelius B., et al. Risk of leukemia following treatment for non-Hodgkin's lymphoma. J. Natl. Cancer Inst. 86 (1994) 1450-1457
6. Costedoat-Chalumeau N., Amoura Z., Aymard G., Sevin O., Wechsler B., Cacoub P., et al. Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. Ann. Intern. Med. 132 (2000) 631-635
7. Ostensen M., Khamashta M., Lockshin M., Parke A., Brucato A., Carp H., et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res. Ther. 8 (2006) 209-228
8. Ozyazgan Y., Yurdakul S., Yazici H., Tunzun B., Iscimen A., Tunzun Y., et al. Low dose cyclosporin versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br. J. Ophthalmol. 76 (1992) 241-243
9. Shahram F., Davatchi F., Chams H., Nadji A., Jamshidi A., Akbarian M., et al. Azathioprine and low dose pulse cyclophosphamide in severe ocular lesions of Behcet's disease. A preliminary report. Adv. Exp. Med. Biol. 528 (2003) 571-573
10. Rosenbaum J.T. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J. Rheumatol. 21 (1994) 123-125
11. Hamza M., Meddeb S., Mili I., and Ouertani A. Bolus de cyclophosphamide et de méthylprednisolone dans l'uvéite de la maladie de Behçet. Résultats préliminaires avec utilisation de nouveaux critères d'évaluation. Ann. Med. Interne (Paris) 143 (1992) 438-441
12. Durrani K., Papaliodis G.N., and Foster C.S. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 111 (2004) 960-965
13. Le Thi Huong D., Amoura Z., Duhaut P., Sbai A., Costedoat N., Wechsler B., et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide therapy. A study in 84 patients. J. Rheumatol. 29 (2002) 2571-2576
14. Masala A., Faedda R., Alagna S., Satta A., Chiarelli G., Rovasio P.P., et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann. Intern. Med. 126 (1997) 292-295
15. Yazici H., Pazarli H., Barnes C.G., Tuzun Y., Ozyazgan Y., Silman A., et al. A controlled trial of azathioprine in Behcet's syndrome. N. Engl. J. Med. 322 (1990) 281-285
16. Newell F.W., and Krill A.E. Treatment of uveitis with azathioprine. Trans. Ophthalmol. Soc. U. K. 87 (1967) 499-511
17. Akpek E.K., Jabs D.A., Tessler H.H., Joondeph B.C., and Foster C.S. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 109 (2002) 1506-1513
18. Becker M.D., Wertheim M.S., Smith J.R., and Rosenbaum J.T. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul. Immunol. Inflamm. 13 (2005) 289-293
19. Kiss S., Ahmed M., Letko E., and Foster C.S. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology 112 (2005) 1066-1071
20. Touitou V., Escande C., Bodaghi B., Cassoux N., Wechsler B., Lemaitre C., et al. Diagnostic et traitement du syndrome de Voght-Koyanagi-Harada. J. Fr. Ophtalmol. 28 (2005) 9-16
21. Foeldvari I., and Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J. Rheumatol. 32 (2005) 362-365
22. Malik A.R., and Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br. J. Ophthalmol. 89 (2005) 806-808
23. Bom S., Zamiri P., and Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul. Immunol. Inflamm. 9 (2001) 35-40
24. Kaplan-Messas A., Barkana Y., Avni I., and Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul. Immunol. Inflamm. 11 (2003) 131-139
25. Samson C.M., Waheed N., Baltatzis S., and Foster C.S. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108 (2001) 1134-1139
26. Davatchi F., Shahram F., Chams H., Jamshidi A.R., Nadji A., Chams C., et al. High dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results. Adv. Exp. Med. Biol. 528 (2003) 579-584
27. Dev S., McGallum R.M., and Jaffe G.J. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology 106 (1999) 111-118
28. Stawell R. Methotrexate in inflammatory eye disease. Ocul. Immunol. Inflamm. 11 (2003) 79-82
29. Barkana Y., Avni I., and Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul. Immunol. Inflamm. 11 (2003) 131-139
30. Shah S.S., Lowder C.Y., Schmitt M.A., Wilke W.S., Kosmorsky G.S., and Meisler D.M. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 99 (1992) 1419-1423
31. Nussenblatt R.B., Palestine A.G., Chan C.C., Stevens Jr. G., Mellow S.D., and Green S.B. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am. J. Ophthalmol. 112 (1991) 138-146
32. Masuda K., Nakajima A., Urayama A., Nakae K., Kogure M., and Inaba G. Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behçet's disease. Lancet 1 (1989) 1093-1096
33. Ozdal P.C., Ortac S., Taskintuna I., and Firat E. Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc. Ophthalmol. 105 (2002) 301-312
34. Sullu Y., Oge I., Erkan D., Ariturk N., and Mohajeri F. Cyclosporin-A therapy in severe uveitis of Behcet's disease. Acta Ophthalmol. Scand. 76 (1998) 96-99
35. Isnard-Bagnis C., Tezenas du Montcel S., Beaufils H., Jouanneau C., Jaudon M.C., Maksud P., et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J. Am. Soc. Nephrol. 13 (2002) 2962-2968
36. Sloper C.M., Powell R.J., and Dua H.S. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106 (1999) 723-728
37. Kilmartin D.J., Forrester J.V., and Dick A.D. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul. Immunol. Inflamm. 6 (1998) 101-109
38. Ishioka M., Ohno S., Nakamura S., Isobe K., Watanabe N., Ishigatsubo Y., et al. FK506 treatment of noninfectious uveitis. Am. J. Ophthalmol. 118 (1994) 723-729
39. Mochizuki M., Masuda K., Sakane T., Ito K., Kogure M., Sugino N., et al. A clinical trial of FK506 in refractory uveitis. Am. J. Ophthalmol. 115 (1993) 763-769
40. Murphy C.C., Greiner K., Plskova J., Duncan L., Frost N.A., Forrester J.V., et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch. Ophthalmol. 123 (2005) 634-641
41. Siepmann K., Huber M., Stubiger N., Deuter C., and Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis. A retrospective analysis of 106 patients. Graefes Arch. Clin. Exp. Ophthalmol. 15 (2005) 1-7
42. Lau C.H., Comer M., and Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin. Experiment. Ophthalmol. 31 (2003) 487-491
43. Sen H.N., Suhler E.B., Al-Khatib S.Q., Djalilian A.R., Nussenblatt R.B., and Buggage R.R. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology 110 (2003) 1750-1755
44. Thorne J.E., Jabs D.A., Qazi F.A., Nguyen Q.D., Kempen J.H., and Dunn J.P. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005;112:1472-7 45 - Baltatzis S, Tufail F, Yu EN, Vredeveld CM, Foster CS. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110 (2003) 1061-1065
45. Baltatzis S., Tufail F., Yu E.N., Vredeveld C.M., and Foster C.S. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110 (2003) 1061-1065
46. Alpsoy E., Durusoy C., Yilmaz E., Ozgurel Y., Ermis O., Yazar S., et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch. Dermatol. 138 (2002) 467-471
47. Calguneri M., Ozturk M.A., Ertenli I., Kiraz S., Apras S., and Ozbalkan Z. Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease : an open study. Ann. Rheum. Dis. 62 (1993) 492-493
48. Wechsler B., Bodaghi B., Huong D.L., Fardeau C., Amoura Z., Cassoux N., et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul. Immunol. Inflamm. 8 (2000) 293-301
49. Kotter I., Vonthein R., Zierhut M., Eckstein A.K., Ness T., Gunaydin I., et al. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial. Semin. Arthritis Rheum. 33 (2004) 311-319
50. Sobaci G., Bayraktar Z., and Bayer A. Interferon alpha-2a treatment for serpiginous choroiditis. Ocul. Immunol. Inflamm. 13 (2005) 59-66
51. Becker M.D., Heiligenhaus A., Hudde T., Storch-Hagenlocher B., Wildemann B., Barisani-Asenbauer T., et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br. J. Ophthalmol. 89 (2005) 1254-1257
52. Bodaghi B., Gendron G., Wechsler B., Cassoux N., Le Thi Huong D., Lemaitre C., et al. Efficacy and tolerance of interferon alpha in the treatment of refractory and sight-threatening uveitis : a monocentric study of 45 patients. Br J Ophthalmol (2006) (in press)
53. Kotter I., Gunaydin I., Zierhut M., and Stubiger N. The use of interferon alpha in Behcet disease: review of the literature. Semin. Arthritis Rheum. 33 (2004) 320-335
54. Linstedt E.W., Baarsma G.S., Kuijpers R.W., and van Hagen P.M. Anti-TNF-α therapy for sight threatening uveitis. Br. J. Ophthalmol. 89 (2005) 533-536
55. Bodaghi B., Bui Quoc E., Wechsler B., Tran T.H., Cassoux N., Le Thi Huong D., et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann. Rheum. Dis. 64 (2005) 962-964
56. Tugal-Tutkun I., Mudun A., Urgancioglu M., Kamali S., Kasapoglu E., Inanc M., et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behçet's disease. An open-label trial. Arthritis Rheum. 52 (2005) 2478-2484